RxCentric.com, Inc.

Name: RxCentric.com, Inc.
Brand: Veradigm

Leader

Driving value through its unique combination of platforms, data, expertise, connectivity, and scale.

Est 2006|Valuation $522.7M|Raised $3.3B|8 Ref Customers

LinkedIn 178K|Website|Web traffic 218K|FTEs 1,844|HQ Chicago, Illinois, US

MarketsAPI Management

Published Oct 20, 2026

01Common complaints

Consider alternatives or a tightly scoped pilot when: 1) Transparent contract terms and predictable renewals are required - Multiple review and complaint sources describe contract and billing friction. Organizations with limited contract governance capacity may experience higher risk. 2) Mobile-first prescribing is a primary requirement - Mobile app ratings and user feedback suggest performing a hands-on mobile pilot prior to committing. 3) Product-specific compliance artifacts must be provided upfront - While Veradigm references SOC 2 Type 2 activity and other program elements, publicly available, product-specific certification artifacts were not consolidated in the materials reviewed; request these artifacts during procurement. 4) The environment has complex integrations and limited capacity to absorb integration risk - Complaint narratives include integration-related operational impacts; where integration risk cannot be mitigated through pilot and testing, evaluate modular alternatives or plan for expanded implementation governance.

Poor fit indicators

Organizations with low tolerance for potential support delays or contract/billing complexity.
Environments where mobile-first prescribing is mission-critical without a validated mobile pilot.
Buyers that require clearly documented, product-specific compliance artifacts before procurement.

Evidence-backed limitations (from sources reviewed)

Mobile app satisfaction was low in the app store snapshot reviewed.
Support responsiveness and contract/billing complaints appear repeatedly in review sites and complaint portals.
Product-specific compliance artifacts (SOC 2, ISO, BAA) were not found in a consolidated, procurement-friendly format in the materials reviewed.

Vendor roadmap

No explicit public roadmap items or dated milestones for these specific products were found in the materials reviewed. Buyers should request product roadmaps and release schedules during procurement.

02Why they buy

Unique selling points supported by sources and vendor materials

Embedded patient-specific price transparency in the prescribing workflow (RxTruePrice).
Vendor-communicated network and connectivity scale metrics reported in corporate materials.
Automation of prior authorization and integration with PDMP and EPCS workflows as part of the prescribing flow.

Areas where competitors may have advantages

Pricing clarity and packaging: some competitors publish clearer tiered pricing tables that can simplify procurement for small practices.
Perceived usability and support: some alternatives may avoid documented support and billing friction seen in Veradigm reviews; this should be validated in comparative pilots.

03Field reports

Review availability challenge: legacy name vs current product names

RxCentric as a legacy acquired entity is not commonly reviewed under that name on modern SaaS review sites. User sentiment for the relevant capabilities is therefore approximated by reviews of Veradigm product lines and app store feedback. This creates a methodology limitation: many reviews address broader Veradigm modules rather than only the ePrescribe and RxTruePrice components.

Review platform summaries

- G2 shows Veradigm with aggregate ratings in reviewer profiles; product-level ratings vary across modules. - Capterra includes both positive and negative feedback, with many comments focused on service/support and billing/contract administration. - Mobile app store reviews for Veradigm ePrescribe indicate low ratings at the time of review, suggesting user dissatisfaction with at least some mobile versions of the application. - Complaint portals include narratives alleging issues with cancellation, billing, and integration; these should be reviewed as procurement risk indicators rather than as definitive product performance evidence. **Interpretation caution:** review site comments and complaint portals are anecdotal and reflect individual experiences; they are relevant for risk assessment but are not a substitute for controlled product evaluation or vendor-provided audit artifacts.

Vendor-published outcomes: RxTruePrice savings

Veradigm reported an internal review of RxTruePrice transactions for a specified period that included metrics such as average cost savings per prescription and aggregated patient cost savings based on the vendor's transaction logs. **Critical evaluation / methodology gaps:** - These are vendor-published results based on internal logs and have not been subjected to independent peer review. The basis for "savings" (baseline price definitions, therapeutic substitution assumptions, fill-rate behavior) is not fully disclosed in the material reviewed.

Vendor-published outcomes: adherence improvement

Veradigm reported a field study indicating perceived improvements in adherence among RxTruePrice users.

Critical evaluation:

The reported result appears to reflect user-observed improvements rather than objective refill, claims, or longitudinal adherence measurements. Buyers seeking quantitative adherence impact should request methodology, raw data, and any independent validation.

04Best fit

Best-fit organization profile (inferred from positioning and pricing)

- Company size: small-to-mid ambulatory practices and groups. The advertised starting price and product framing indicate SMB suitability while vendor materials also reference enterprise integration capability. - Industries: outpatient medical practices and specialties with significant prescribing volumes and prior authorization workload. - Roles / personas: practice owners, medical directors, COOs, practice administrators, IT managers (for integrations); end users include prescribers, clinical staff, refill teams, and prior authorization coordinators.

Strong fit scenarios

Organizations that want:
- Patient-specific real-time benefit and price transparency during prescribing
- ePA automation and embedded PDMP and EPCS workflows
- A single prescribing workflow across devices (with the caveat that mobile performance should be validated in pilots)

05The pitch

What the product does (objective value proposition)

RxCentric appears to be the legacy entity behind e-prescribing and prescription-pricing transparency capabilities currently offered under Veradigm, including Veradigm ePrescribe and the embedded pricing tool RxTruePrice. The RxCentric capability set, as presented through Veradigm, supports: - Electronic prescribing (eRx) including EPCS (controlled substances) and PDMP workflow support. - Real-time prescription benefit / price transparency via RxTruePrice (patient-specific pricing and therapeutic alternatives). - Electronic prior authorization (ePA) workflow functionality included with the ePrescribe offering. These capabilities are implemented as workflow-embedded tools designed to address prescription abandonment, support medication adherence, and reduce administrative tasks associated with prescribing.

Target market and positioning

Primary buyers and users: ambulatory providers, small-to-mid sized practices, and EHR vendors seeking an enterprise integration option.
Positioning theme: point-of-care prescribing with real-time benefit/price information and automated prior authorization within the prescribing workflow.

Get a comprehensive analysis of RxCentric.com, Inc. including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 20, 2026

01Common complaints

Consider alternatives or a tightly scoped pilot when:

Transparent contract terms and predictable renewals are required

Multiple review and complaint sources describe contract and billing friction. Organizations with limited contract governance capacity may experience higher risk.

Mobile-first prescribing is a primary requirement

Mobile app ratings and user feedback suggest performing a hands-on mobile pilot prior to committing.

Product-specific compliance artifacts must be provided upfront

While Veradigm references SOC 2 Type 2 activity and other program elements, publicly available, product-specific certification artifacts were not consolidated in the materials reviewed; request these artifacts during procurement.

The environment has complex integrations and limited capacity to absorb integration risk

Complaint narratives include integration-related operational impacts; where integration risk cannot be mitigated through pilot and testing, evaluate modular alternatives or plan for expanded implementation governance.

Poor fit indicators

Organizations with low tolerance for potential support delays or contract/billing complexity.
Environments where mobile-first prescribing is mission-critical without a validated mobile pilot.
Buyers that require clearly documented, product-specific compliance artifacts before procurement.

Evidence-backed limitations (from sources reviewed)

Mobile app satisfaction was low in the app store snapshot reviewed.
Support responsiveness and contract/billing complaints appear repeatedly in review sites and complaint portals.
Product-specific compliance artifacts (SOC 2, ISO, BAA) were not found in a consolidated, procurement-friendly format in the materials reviewed.

Vendor roadmap

No explicit public roadmap items or dated milestones for these specific products were found in the materials reviewed. Buyers should request product roadmaps and release schedules during procurement.

02Why they buy

Unique selling points supported by sources and vendor materials

Embedded patient-specific price transparency in the prescribing workflow (RxTruePrice).
Vendor-communicated network and connectivity scale metrics reported in corporate materials.
Automation of prior authorization and integration with PDMP and EPCS workflows as part of the prescribing flow.

Areas where competitors may have advantages

Pricing clarity and packaging: some competitors publish clearer tiered pricing tables that can simplify procurement for small practices.
Perceived usability and support: some alternatives may avoid documented support and billing friction seen in Veradigm reviews; this should be validated in comparative pilots.

03Field reports

Review availability challenge: legacy name vs current product names

Review platform summaries

G2 shows Veradigm with aggregate ratings in reviewer profiles; product-level ratings vary across modules.
Capterra includes both positive and negative feedback, with many comments focused on service/support and billing/contract administration.
Mobile app store reviews for Veradigm ePrescribe indicate low ratings at the time of review, suggesting user dissatisfaction with at least some mobile versions of the application.
Complaint portals include narratives alleging issues with cancellation, billing, and integration; these should be reviewed as procurement risk indicators rather than as definitive product performance evidence.

Interpretation caution: review site comments and complaint portals are anecdotal and reflect individual experiences; they are relevant for risk assessment but are not a substitute for controlled product evaluation or vendor-provided audit artifacts.

Vendor-published outcomes: RxTruePrice savings

Critical evaluation / methodology gaps:

These are vendor-published results based on internal logs and have not been subjected to independent peer review. The basis for "savings" (baseline price definitions, therapeutic substitution assumptions, fill-rate behavior) is not fully disclosed in the material reviewed.

Vendor-published outcomes: adherence improvement

Veradigm reported a field study indicating perceived improvements in adherence among RxTruePrice users.

Critical evaluation:

The reported result appears to reflect user-observed improvements rather than objective refill, claims, or longitudinal adherence measurements. Buyers seeking quantitative adherence impact should request methodology, raw data, and any independent validation.

04Best fit

Best-fit organization profile (inferred from positioning and pricing)

Company size: small-to-mid ambulatory practices and groups. The advertised starting price and product framing indicate SMB suitability while vendor materials also reference enterprise integration capability.
Industries: outpatient medical practices and specialties with significant prescribing volumes and prior authorization workload.
Roles / personas: practice owners, medical directors, COOs, practice administrators, IT managers (for integrations); end users include prescribers, clinical staff, refill teams, and prior authorization coordinators.

Strong fit scenarios

Organizations that want:
- Patient-specific real-time benefit and price transparency during prescribing
- ePA automation and embedded PDMP and EPCS workflows
- A single prescribing workflow across devices (with the caveat that mobile performance should be validated in pilots)

05The pitch

What the product does (objective value proposition)

The RxCentric capability set, as presented through Veradigm, supports:

Electronic prescribing (eRx) including EPCS (controlled substances) and PDMP workflow support.
Real-time prescription benefit / price transparency via RxTruePrice (patient-specific pricing and therapeutic alternatives).
Electronic prior authorization (ePA) workflow functionality included with the ePrescribe offering.

These capabilities are implemented as workflow-embedded tools designed to address prescription abandonment, support medication adherence, and reduce administrative tasks associated with prescribing.

Target market and positioning

Primary buyers and users: ambulatory providers, small-to-mid sized practices, and EHR vendors seeking an enterprise integration option.
Positioning theme: point-of-care prescribing with real-time benefit/price information and automated prior authorization within the prescribing workflow.

Get a comprehensive analysis of RxCentric.com, Inc. including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →